Poolbeg Pharma plc (LON:POLB), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has announced that, further to its announcement in March 2022, the construction of the computational artificial intelligence
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost
EncOVac, a consortium led by Poolbeg Pharma, has been awarded €2.3m in funding from the Irish Government’s Disruptive Technologies Innovation Fund (DTIF). Poolbeg Pharma is an infectious disease firm spun
Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has announced that it will be holding a Capital Markets Day
Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has announced that ‘EncOVac’, a consortium led by Poolbeg Pharma, has
Poolbeg Pharma says it has made a breakthrough in its Artificial Intelligence (AI) program with partner OneThree Biotech, Inc. through the discovery of novel drug targets for the treatment of
Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it has made a significant breakthrough in its Artificial
An infectious disease pharmaceutical company has joined forces with a specialist micro encapsulation company based in Cork to develop oral vaccines. Poolbeg Pharma based in Dublin has partnered with Carrigtwohill-based
Infectious disease pharmaceutical company Poolbeg Pharma updated the market on its intellectual property (IP) position around ‘POLB 001’ on Tuesday, which it described as a small molecule immunomodulator for the treatment of
Poolbeg Pharma has been granted patents by the US Patent and Trademark Office (USPTO) for POLB 001, a small molecule immunomodulator for the treatment of severe influenza and POLB 002,
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
